OPUS GENETICS INC (IRD) Fundamental Analysis & Valuation

NASDAQ:IRD • US67577R1023

Current stock price

5.57 USD
+0.21 (+3.92%)
At close:
5.52 USD
-0.05 (-0.9%)
After Hours:

This IRD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. IRD Profitability Analysis

1.1 Basic Checks

  • In the past year IRD has reported negative net income.
  • IRD had a negative operating cash flow in the past year.
  • IRD had negative earnings in 4 of the past 5 years.
  • In the past 5 years IRD reported 4 times negative operating cash flow.
IRD Yearly Net Income VS EBIT VS OCF VS FCFIRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M

1.2 Ratios

  • IRD's Return On Assets of -98.70% is on the low side compared to the rest of the industry. IRD is outperformed by 75.39% of its industry peers.
  • With a Return On Equity value of -323.11%, IRD is not doing good in the industry: 74.42% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -98.7%
ROE -323.11%
ROIC N/A
ROA(3y)-91.1%
ROA(5y)-90.83%
ROE(3y)-189.38%
ROE(5y)-156.92%
ROIC(3y)N/A
ROIC(5y)N/A
IRD Yearly ROA, ROE, ROICIRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for IRD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IRD Yearly Profit, Operating, Gross MarginsIRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. IRD Health Analysis

2.1 Basic Checks

  • IRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, IRD has more shares outstanding
  • The number of shares outstanding for IRD has been increased compared to 5 years ago.
  • IRD has a worse debt/assets ratio than last year.
IRD Yearly Shares OutstandingIRD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
IRD Yearly Total Debt VS Total AssetsIRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • IRD has an Altman-Z score of 0.20. This is a bad value and indicates that IRD is not financially healthy and even has some risk of bankruptcy.
  • IRD's Altman-Z score of 0.20 is in line compared to the rest of the industry. IRD outperforms 58.91% of its industry peers.
  • A Debt/Equity ratio of 0.07 indicates that IRD is not too dependend on debt financing.
  • IRD has a worse Debt to Equity ratio (0.07) than 61.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 0.2
ROIC/WACCN/A
WACC9.15%
IRD Yearly LT Debt VS Equity VS FCFIRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 6.43 indicates that IRD has no problem at all paying its short term obligations.
  • The Current ratio of IRD (6.43) is better than 64.34% of its industry peers.
  • A Quick Ratio of 6.43 indicates that IRD has no problem at all paying its short term obligations.
  • IRD has a better Quick ratio (6.43) than 64.92% of its industry peers.
Industry RankSector Rank
Current Ratio 6.43
Quick Ratio 6.43
IRD Yearly Current Assets VS Current LiabilitesIRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. IRD Growth Analysis

3.1 Past

  • IRD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.18%, which is quite good.
  • The Revenue has grown by 29.15% in the past year. This is a very strong growth!
  • Measured over the past years, IRD shows a very negative growth in Revenue. The Revenue has been decreasing by -29.11% on average per year.
EPS 1Y (TTM)18.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.82%
Revenue 1Y (TTM)29.15%
Revenue growth 3Y-29.11%
Revenue growth 5YN/A
Sales Q2Q%-10.16%

3.2 Future

  • The Earnings Per Share is expected to grow by 22.79% on average over the next years. This is a very strong growth
  • IRD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 111.38% yearly.
EPS Next Y41.08%
EPS Next 2Y17.33%
EPS Next 3Y10.84%
EPS Next 5Y22.79%
Revenue Next Year20.82%
Revenue Next 2Y20.21%
Revenue Next 3Y95.71%
Revenue Next 5Y111.38%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IRD Yearly Revenue VS EstimatesIRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
IRD Yearly EPS VS EstimatesIRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. IRD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IRD. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRD Price Earnings VS Forward Price EarningsIRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRD Per share dataIRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.33%
EPS Next 3Y10.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IRD Dividend Analysis

5.1 Amount

  • IRD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IRD Fundamentals: All Metrics, Ratios and Statistics

OPUS GENETICS INC

NASDAQ:IRD (4/13/2026, 8:00:02 PM)

After market: 5.52 -0.05 (-0.9%)

5.57

+0.21 (+3.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10
Earnings (Next)05-13
Inst Owners31.48%
Inst Owner ChangeN/A
Ins Owners7.59%
Ins Owner Change-13.52%
Market Cap396.31M
Revenue(TTM)14.20M
Net Income(TTM)-49.59M
Analysts83.33
Price Target10.13 (81.87%)
Short Float %3.69%
Short Ratio1.93
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-118.58%
Min EPS beat(2)-146.76%
Max EPS beat(2)-90.4%
EPS beat(4)2
Avg EPS beat(4)-47.54%
Min EPS beat(4)-146.76%
Max EPS beat(4)42.04%
EPS beat(8)3
Avg EPS beat(8)-40.84%
EPS beat(12)4
Avg EPS beat(12)-41.37%
EPS beat(16)8
Avg EPS beat(16)-23.99%
Revenue beat(2)1
Avg Revenue beat(2)6.88%
Min Revenue beat(2)-0.87%
Max Revenue beat(2)14.62%
Revenue beat(4)2
Avg Revenue beat(4)5.98%
Min Revenue beat(4)-29.45%
Max Revenue beat(4)39.62%
Revenue beat(8)4
Avg Revenue beat(8)2.27%
Revenue beat(12)6
Avg Revenue beat(12)20.74%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)28.49%
PT rev (3m)27.29%
EPS NQ rev (1m)-17.54%
EPS NQ rev (3m)-15.91%
EPS NY rev (1m)-15.27%
EPS NY rev (3m)-26.89%
Revenue NQ rev (1m)-4.72%
Revenue NQ rev (3m)-4.3%
Revenue NY rev (1m)-4.16%
Revenue NY rev (3m)-8.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 27.92
P/FCF N/A
P/OCF N/A
P/B 25.82
P/tB 25.82
EV/EBITDA N/A
EPS(TTM)-0.9
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0.2
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -98.7%
ROE -323.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-91.1%
ROA(5y)-90.83%
ROE(3y)-189.38%
ROE(5y)-156.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.43
Quick Ratio 6.43
Altman-Z 0.2
F-Score4
WACC9.15%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.82%
EPS Next Y41.08%
EPS Next 2Y17.33%
EPS Next 3Y10.84%
EPS Next 5Y22.79%
Revenue 1Y (TTM)29.15%
Revenue growth 3Y-29.11%
Revenue growth 5YN/A
Sales Q2Q%-10.16%
Revenue Next Year20.82%
Revenue Next 2Y20.21%
Revenue Next 3Y95.71%
Revenue Next 5Y111.38%
EBIT growth 1Y-14.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year157.72%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.84%
OCF growth 3YN/A
OCF growth 5YN/A

OPUS GENETICS INC / IRD Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for OPUS GENETICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to IRD.


Can you provide the valuation status for OPUS GENETICS INC?

ChartMill assigns a valuation rating of 0 / 10 to OPUS GENETICS INC (IRD). This can be considered as Overvalued.


What is the profitability of IRD stock?

OPUS GENETICS INC (IRD) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for IRD stock?

The Earnings per Share (EPS) of OPUS GENETICS INC (IRD) is expected to grow by 41.08% in the next year.